Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
2.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
3.
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
4.
Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
5.
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market
6.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
7.
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
8.
Stakeholder Opinions: Heart Failure - When drugs do not work
9.
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
10.
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
Best Sellers:
1.
Primary Brain Cancer
2.
Drug Delivery Global Industry Guide
3.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
4.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
5.
BioNewsCast Press Release Distribution Service
6.
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
7.
Cell Therapy - Technologies, Markets and Companies
8.
Cytogenetics - technologies, markets and companies
9.
Molecular Diagnostics Markets
10.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
Good Manufacturing Practices 3rd Edition
A Guide to Good Manufacturing Practices 3rd Edition
By Alex D. Kanarek, Ph.D.
Published: July, 2006
Newly Revised to Include the Latest FDA Regulations
Scope of Guide
D&MD's updated Good Manufacturing Practices professional development guide provides pharmaceutical and biological companies of all sizes with assistance in regulatory compliance. The guide examines the new FDA Guidance for Industry documents and a new amendment covering an exemption for investigational drugs in Phase 1 studies. The guide is addressed particularly to smaller sized companies, perhaps those with their first new drug, working on this extra challenge to their capabilities.
Analyzing the contents of the latest versions of the GMP rules laid down by the USA, Canada and Japan, ICH, the EC and WHO, this guide provides pharmaceutical and biological companies of all sizes with assistance in compliance with these rules. The guide is addressed particularly to smaller sized companies, perhaps those with their first new drug, working on this extra challenge to their capabilities.
Questions Answered
> What drug products are covered by the cGMP regulations?
> At what stage in a drug's development do the cGMP regulations become effective?
> How do we apply these regulations to our manufacturing operations?
> How do we ensure we will pass a cGMP inspection?
Target Audience
This guide will prove beneficial to the following professionals involved in Pharmaceutical, Biopharmaceutical and Biological development and manufacturing:
> Heads of Manufacturing
> QA, QC
> Regulatory Affairs
> Product & Process Development Scientists
> Manufacturing Supervisory Staff
> QA Auditing Staff
> Validation Experts
> GMP Trainers
Jul-06 Pages 423 PDF Format
The Author
Price: $895.00 / GBP447.50
Good Manufacturing Practices 3rd Edition
A Guide to Good Manufacturing Practices 3rd Edition
By Alex D. Kanarek, Ph.D.
Published: July, 2006
Newly Revised to Include the Latest FDA Regulations
Scope of Guide
D&MD's updated Good Manufacturing Practices professional development guide provides pharmaceutical and biological companies of all sizes with assistance in regulatory compliance. The guide examines the new FDA Guidance for Industry documents and a new amendment covering an exemption for investigational drugs in Phase 1 studies. The guide is addressed particularly to smaller sized companies, perhaps those with their first new drug, working on this extra challenge to their capabilities.
Analyzing the contents of the latest versions of the GMP rules laid down by the USA, Canada and Japan, ICH, the EC and WHO, this guide provides pharmaceutical and biological companies of all sizes with assistance in compliance with these rules. The guide is addressed particularly to smaller sized companies, perhaps those with their first new drug, working on this extra challenge to their capabilities.
Questions Answered
> What drug products are covered by the cGMP regulations?
> At what stage in a drug's development do the cGMP regulations become effective?
> How do we apply these regulations to our manufacturing operations?
> How do we ensure we will pass a cGMP inspection?
Target Audience
This guide will prove beneficial to the following professionals involved in Pharmaceutical, Biopharmaceutical and Biological development and manufacturing:
> Heads of Manufacturing
> QA, QC
> Regulatory Affairs
> Product & Process Development Scientists
> Manufacturing Supervisory Staff
> QA Auditing Staff
> Validation Experts
> GMP Trainers
Jul-06 Pages 423 PDF Format
The Author
Price: $895.00 / GBP447.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.